New scan may sharpen radiation for Fast-Growing brain cancers

NCT ID NCT05608395

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 2 trial tested whether a special PET/CT scan using 11C-methionine could help doctors better plan radiation therapy for people with glioblastoma, the most common and aggressive brain cancer. The study focused on patients whose tumors grew back quickly after surgery (rapid early progression). 33 participants received the scan, and their radiation plans were adjusted based on the results. The goal was to see if this approach could improve how long patients lived without their cancer worsening.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
11C-methionine (a radioactive amino acid used in PET/CT scans)
What this could lead to
If successful, this approach could help doctors create more precise radiotherapy plans for glioblastoma patients whose tumors grow back quickly after surgery, potentially improving their outcomes.
What could go wrong
This is a small, early-phase study with only 33 participants, and it compares results to historical data rather than a control group. The benefit of adjusting radiotherapy based on this scan is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Masaryk Memorial Cancer Institute

    Brno, Czech Republic, 65653, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.